Ge Zhang-Ge
Sar, 999077, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Intracellular sclerostin promotes tumor progression and metastasis as a potential therapeutic target in triple-negative breast cancer.
Journal: Cell reports. Medicine
Published: July 19, 2025
Author Correction: Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation.
Journal: Nature communications
Published: June 19, 2025
Osteoblastic sclerostin loop3-LRP4 interaction required by sclerostin to inhibit bone formation.
Journal: Bone research
Published: February 06, 2025
Discovery of 3-amide-pyrimidine-based derivatives as potential fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia.
Journal: Bioorganic & medicinal chemistry letters
Published: October 31, 2024
Regulating chemoresistance and cancer stemness: the CDH17-YAP pathway in distinct cellular states of lung cancer CTC clusters.
Journal: Cellular & molecular biology letters
Published: July 24, 2024
Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release.
Journal: Journal of translational medicine
Published: March 19, 2024
Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity.
Journal: Nature communications
Published: March 16, 2024
Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy.
Journal: Cancer letters
Published: February 23, 2024
Discovery of the small molecular inhibitors against sclerostin loop3 as potential anti-osteoporosis agents by structural based virtual screening and molecular design.
Journal: European journal of medicinal chemistry
Published: January 14, 2024
Last Updated: 09/26/2026